News OMass attracts $420m Roche wager on IBD programme UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.
News Roche breaks ground on US manufacturing facility Roche's Genentech unit has started work on a $700m manufacturing facility in North Carolina, part of a promised $50bn US investment programme.
Market Access Biotech opportunities in North Carolina, with Kyle Touchston... From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.
News Genentech's Bittenbender named board chair at BIO Genentech's Fritz Bittenbender becomes chair of the Biotechnology Innovation Organization at a challenging time for the sector.
News Roche ends the 30-year US hiatus in new stroke drugs Genentech has won FDA approval for its clot-buster TNKase as a treatment for acute ischaemic stroke, after almost abandoning the project in 2023.
News Genentech buys Regor's next-gen CDK inhibitors for $850M Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million.
News Sandoz launches first biosimilar Tysabri in US Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.